Articles by Patricia Van Arnum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Patricia Van Arnum

Boom or Bust for Pharma on a New US-EU Trade Pact?

Negotiations begin this week on the Transatlantic Trade and Investment Partnership, a new trade pact between the United States and European Union. What will be the implications for the pharmaceutical industry?
Jul 10, 2013

Negotiations begin this week on the Transatlantic Trade and Investment Partnership, a new trade pact between the United States and European Union. What will be the implications for the pharmaceutical industry?

Gauging Investment in High-Potency Manufacturing

Contract service providers expand capabilities in API and finished product manufacturing to meet demand for high-potency drugs.
Jul 2, 2013

Contract service providers expand capabilities in API and finished product manufacturing to meet demand for high-potency drugs.

Strengthening the Supply Chain for Pharmaceutical Ingredients

The US and EU move forward with measures to fortify the pharmaceutical supply chain.
Jul 2, 2013

The US and EU move forward with measures to fortify the pharmaceutical supply chain.

PhRMA, BIO Join Newly Formed Coalition Advocating for Fair Trade with India

The Alliance for Fair Trade with India is seeking action to resolve discriminatory trade practices and improved protection of intellectual property rights.
Jun 25, 2013

The Alliance for Fair Trade with India is seeking action to resolve discriminatory trade practices and improved protection of intellectual property rights.

Elan Initiates Formal Sale Process of Company

The move follows rejection of Elan shareholders of certain key deals and withdrawal of Royalty Pharma bid.
Jun 18, 2013

The move follows rejection of Elan shareholders of certain key deals and withdrawal of Royalty Pharma bid.

Elan Board Rejects Multibillion Takeover Bid from Royalty Pharma

Elan urges its shareholders to reject bid in an upcoming meeting on June 17.
Jun 11, 2013

Elan urges its shareholders to reject bid in an upcoming meeting on June 17.

Aesica in an Expansion Mode

The CMO Aesica has used a combination of organic growth and acquisitions to build its business and is seeking to expand its geographic footprint.
Jun 5, 2013

The CMO Aesica has used a combination of organic growth and acquisitions to build its business and is seeking to expand its geographic footprint.

A Pharma Industry Mid-Year Review and Outlook

Emerging markets remain strong as established markets fare less well.
Jun 5, 2013

Emerging markets remain strong as established markets fare less well.

Pharma Industry Participates in Global Health Initiatives

Highlights from the 66th World Health Assembly and the pharmaceutical industrys role in addressing noncommunicable diseases, mental and neurological disorders, R&D for diseases of the developing world, counterfeit medicines, the global vaccine action plan, and neglected tropical diseases.
Jun 5, 2013

Highlights from the 66th World Health Assembly and the pharmaceutical industry?s role in addressing noncommunicable diseases, mental and neurological disorders, R&D for diseases of the developing world, counterfeit medicines, the global vaccine action plan, and neglected tropical diseases.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here